Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
05/06/2025
Dutch Prime Minister: Wilders' behavior is unnecessary and irresponsible.
Latest
1 m ago
The increase in steel and aluminum tariffs will push up prices of various goods, some by several thousand dollars.
2 m ago
Hengrui Medicine: Citrate Sodium Blood Filtration Replacement Solution Approved for Market Launch
2 m ago
Hong Kong Hang Seng Index rose by 1.07%. Hang Seng Tech Index rose by 1.93%.
2 m ago
The Hang Seng Index closed up 1.07%, with consumer stocks generally pulling back.
2 m ago
Hengrui Medicine announced that its subsidiaries Suzhou Shendia Biopharmaceutical Co., Ltd. and Shanghai Shendi Pharmaceutical Co., Ltd. have received approval from the National Medical Products Administration to conduct clinical trials for the injection SHR-A1811, the Adabelli monoclonal antibody injection, and the sorafenib apple acid capsule. The clinical trials will begin soon. The injection SHR-A1811 will be used in combination with anti-tumor drugs for the treatment of solid tumors in an open, multi-center phase Ib/II clinical study. The sorafenib apple acid capsule will be used in combination with the injection of carrizumab monoclonal antibody for the treatment of recurrent or metastatic cervical cancer patients who have previously failed platinum-based chemotherapy but have not received treatment with bevacizumab monoclonal antibody. Up to now, the total research and development investment in the injection SHR-A1811 project is about 1.17 billion yuan, in the Adabelli monoclonal antibody injection project about 815 million yuan, and in the sorafenib apple acid capsule project about 255 million yuan.
See all latest
